I. Incidence and epidemiology Currently, primary prevention of cervical cancer is possible with the highly effective human papillomavirus vaccination, and secondary prevention has been advanced with the advent of the more sensitive HPV DNA test, which has improved the traditional Pap cytology screening program. Staging and risk assessment Tumor size, staging, depth of tumor infiltration, lymph node status, lymphovascular interstitial infiltration, and histologic subtypes are included in the tumor risk assessment. Lymph node status and the number of involved lymph nodes are the most important prognostic factors. II. Management of localized/limited disease 1. Radiotherapy for locally advanced cervical cancer For stage IB2-IVA cervical cancer with larger tumors, radiotherapy has been the standard of care for nearly 20 years, and studies have shown that combined radiotherapy can achieve improved disease-free survival and overall survival compared with standard radiotherapy/hydroxyurea. The most commonly used regimen is cisplatin 40 mg/m2 once weekly, although a meta-analysis has reported that non-platinum drugs can also provide significant benefit. 2. Adjuvant therapy Female patients with risk factors in pathology specimens showing intermediate to high risk should receive adjuvant therapy after hysterectomy. Patients with intermediate risk cervical cancer do not require further adjuvant therapy, but adjuvant CRT is recommended for high risk patients. 3. Management of advanced/metastatic disease If a patient has a PS <2 score and no formal contraindications, palliative chemotherapy is appropriate and aims to relieve symptoms and improve quality of life. Studies have shown that a dual regimen of cisplatin plus topotecan or paclitaxel is superior to cisplatin monotherapy in terms of remission rates and progression-free survival. For metastatic or recurrent cervical cancer, the preferred first-line treatment regimen is considered to be paclitaxel and cisplatin in combination with bevacizumab, based on the trade-off between efficacy and toxicity. For patients who are not suitable for cisplatin, a combination of paclitaxel and carboplatin may be considered as an alternative. For patients with FIGO stage IA1, conization is recommended as the preferred diagnostic and radical treatment for those with negative borders and no clinical contraindication to surgery. For patients with LVSI and increased risk of lymph node involvement, PLND is recommended. some patients should be considered for sentinel lymph node biopsy or hysterectomy [II, B]. For patients with FIGO stage IA2 who wish to preserve reproductive function, the standard procedure is cone biopsy or radical hysterectomy with pelvic lymph node dissection. Scientific evidence suggests that hysterectomy with pelvic lymph node dissection is the most appropriate surgical treatment for patients with tumors ≤2 cm in diameter who wish to preserve their fertility. For tumors > 2 cm, conization or hysterectomy after NACT is also a valid option. Follow-up, long-term significance and survival A physician experienced in cancer surveillance should conduct follow-up visits with a thorough physical examination, including pelvic-rectal examination and taking patient history. A CT or PET/CT scan should be performed depending on clinical indications. A reasonable follow-up schedule includes follow-up visits every 3-6 months for the first 2 years and every 6-12 months for the third to fifth years. After 5 years of follow-up and no recurrence, patients should return to the hospital once a year for a general population-based physical examination and pelvic examination.